Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

In 2006, a Rise in Ophthalmic Surgeries

This article was originally published in Start Up

Executive Summary

The diseases of the eye--cataracts, age-related macular degeneration and presbyopia--are largely degenerative conditions that are the result of aging and are every bit as prevalent as cardiovascular disease and the aches and pains that accompany joint degeneration. In 2006, ophthalmic surgical procedures represented approximately 23.2% of all surgeries performed in the US, according to "US Surgical Procedure Volumes," a report recently issued by the Medtech Insight division of Windhover Information, and procedure numbers are expected to climb at a compound annual growth rate of 4.2% through 2014.

You may also be interested in...



Deal Statistics Quarterly, Q1 2007

We present another installment of our quarterly review of dealmaking-for January-March 2007. Our data comes from Windhover's Strategic Transactions Database, which covers deal activity within the pharmaceutical/biotechnology, medical device, and in vitro diagnostics and research industries.

Deal Statistics Quarterly, Q1 2007

We present another installment of our quarterly review of dealmaking-for January-March 2007. Our data comes from Windhover's Strategic Transactions Database, which covers deal activity within the pharmaceutical/biotechnology, medical device, and in vitro diagnostics and research industries.

An Early Peek at Glaucoma Devices

The clinical community has long been searching for a safe and effective surgical alternative to drugs for glaucoma, but the field has moved slowly. A decade ago, non-invasive laser procedures began earning a place as a second-line therapy with limited durability. Invasive surgeries are reserved for end-stage glaucoma because of their complexity, their serious complications, and their high failure rates. Venture firms believe a large, unmet clinical need represents a new $1 billion device market, and the pace of glaucoma device company creation is picking up.

Related Content

Related Companies

Related Deals

Latest Headlines
See All
UsernamePublicRestriction

Register

SC091376

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel